|
1
|
Poland A, Palen D and Glover E: Tumour
promotion by TCDD in skin of HRS/J hairless mice. Nature.
300:271–273. 1982. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murray IA, Patterson AD and Perdew GH:
Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat
Rev Cancer. 14:801–814. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyer BK, Pray-Grant MG, Vanden Heuvel JP
and Perdew GH: Hepatitis B virus X-associated protein 2 is a
subunit of the unliganded aryl hydrocarbon receptor core complex
and exhibits transcriptional enhancer activity. Mol Cell Biol.
18:978–88. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou S, Liu J and Chowbay B: Polymorphism
of human cytochrome P450 enzymes and its clinical impact. Drug
Metab Rev. 41:89–295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stanford EA, Ramirez-Cardenas A, Wang Z,
Novikov O, Alamoud K, Koutrakis P, Mizgerd JP, Genco CA,
Kukuruzinska M, Monti S, et al: Role for the Aryl hydrocarbon
receptor and diverse ligands in oral squamous cell carcinoma
migration and tumorigenesis. Mol Cancer Res. 14:696–706. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quattrochi LC and Tukey RH: Nuclear uptake
of the Ah (dioxin) receptor in response to omeprazole:
Transcriptional activation of the human CYP1A1 gene. Mol Pharmacol.
43:504–508. 1993.PubMed/NCBI
|
|
7
|
Singh SU, Casper RF, Fritz PC, Sukhu B,
Ganss B, Girard B Jr, Savouret JF and Tenenbaum HC: Inhibition of
dioxin effects on bone formation in vitro by a newly described aryl
hydrocarbon receptor antagonist, resveratrol. J Endocrinol.
167:183–195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JE and Safe S: Involvement of a
post-transcriptional mechanism in the inhibition of CYP1A1
expression by resveratrol in breast cancer cells. Biochem
Pharmacol. 62:1113–1124. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He H, Zhao Y, Chen X, Zheng Y, Wu X, Wang
R, Li T, Yu Q, Jing J, Ma L, et al: Quantitative determination of
trans-polydatin, a natural strong anti-oxidative compound, in rat
plasma and cellular environment of a human colon adenocarcinoma
cell line for pharmacokinetic studies. J Chromatogr B Analyt
Technol Biomed Life Sci. 855:145–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Henry-Vitrac C, Desmoulière A, Girard D,
Mérillon JM and Krisa S: Transport, deglycosylation, and metabolism
of trans-piceid by small intestinal epithelial cells. Eur J Nutr.
45:376–382. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rotches-Ribalta M, Andres-Lacueva C,
Estruch R, Escribano E and Urpi-Sarda M: Pharmacokinetics of
resveratrol metabolic profile in healthy humans after moderate
consumption of red wine and grape extract tablets. Pharmacol Res.
66:375–382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ravagnan GP: Extracts from spermatophyte
plants with antitumor activity Euoropean Patent EP1292319B1. Filed
May 29, 2001; issued Aug 15. 2002
|
|
13
|
Wang C, Luo Y, Lu J, Wang Y and Sheng G:
Polydatin induces apoptosis and inhibits growth of acute monocytic
leukemia cells. J Biochem Mol Toxicol. 30:200–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao WJ, Wu K, Wang C and Wan DM:
Polydatin-induced cell apoptosis and cell cycle arrest are
potentiated by Janus kinase 2 inhibition in leukemia cells. Mol Med
Rep. 13:3297–3302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J
and Fan S: Polydatin inhibits growth of lung cancer cells by
inducing apoptosis and causing cell cycle arrest. Oncol Lett.
7:295–301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Maria S, Scognamiglio I, Lombardi A,
Amodio N, Caraglia M, Cartenì M, Ravagnan G and Stiuso P:
Polydatin, a natural precursor of resveratrol, induces cell cycle
arrest and differentiation of human colorectal Caco-2 cell. J
Transl Med. 11:2642013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hogg SJ, Chitcholtan K, Hassan W, Sykes PH
and Garrill A: Resveratrol, acetyl-resveratrol, and polydatin
exhibit antigrowth activity against 3D cell aggregates of the
SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstet Gynecol Int.
2015:2795912015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hughes D, Guttenplan JB, Marcus CB,
Subbaramaiah K and Dannenberg AJ: Heat shock protein 90 inhibitors
suppress aryl hydrocarbon receptor-mediated activation of CYP1A1
and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res.
1:485–493. 2008. View Article : Google Scholar
|
|
19
|
Tsuji N, Fukuda N, Nagata Y, Okada H, Haga
A, Hatakeyama S, Yoshida S, Okamoto T, Hosaka M, Sekine K, et al:
The activation mechanism of the aryl hydrocarbon receptor (AhR) by
molecular chaperone HSP-90. FEBS Open Bio. 4:796–803. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salzano M, Marabotti A, Milanesi L and
Facchiano A: Human aryl-hydrocarbon receptor and its interaction
with dioxin and physiological ligands investigated by molecular
modelling and docking simulations. Biochem Biophys Res Commun.
413:176–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bryne M, Koppang HS, Lilleng R, Stene T,
Bang G and Dabelsteen E: New malignancy grading is a better
prognostic indicator than Broder's grading in oral squamous cell
carcinomas. J Oral Pathol Med. 18:432–437. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martano M, Carella F, Squillacioti C,
Restucci B, Mazzotta M, Lo Muzio L and Maiolino P: Metallothionein
expression in canine cutaneous apocrine gland tumors. Anticancer
Res. 32:747–752. 2012.PubMed/NCBI
|
|
23
|
John K, Lahoti TS, Wagner K, Hughes JM and
Perdew GH: The Ah receptor regulates growth factor expression in
head and neck squamous cell carcinoma cell lines. Mol Carcinog.
53:765–76. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
DiNatale BC, Smith K, John K, Krishnegowda
G, Amin SG and Perdew GH: Ah receptor antagonism represses head and
neck tumor cell aggressive phenotype. Mol Cancer Res. 10:1369–1379.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin XF, Chen J, Mao W, Wang YH and Chen
MH: Downregulation of aryl hydrocarbon receptor expression
decreases gastric cancer cell growth and invasion. Oncol Rep.
30:364–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsai CH, Li CH, Cheng YW, Lee CC, Liao PL,
Lin CH, Huang SH and Kang JJ: The inhibition of lung cancer cell
migration by AhR-regulated autophagy. Sci Rep. 7:419272017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brooks J and Eltom SE: Malignant
transformation of mammary epithelial cells by ectopic
overexpression of the aryl hydrocarbon receptor. Curr Cancer Drug
Targets. 11:654–669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al-Dhfyan A, Alhoshani A and Korashy HM:
Aryl hydrocarbon receptor/Cytochrome P450 1A1 pathway mediates
breast cancer stem cells expansion through PTEN inhibition and
β-Catenin and Akt activation. Mol Cancer. 16:692017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Androutsopoulos VP, Tsatsakis AM and
Spandidos DA: Cytochrome P450 CYP1A1: Wider roles Androutsopoulos
in cancer progression and prevention. BMC Cancer. 9:1872009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moyer BJ, Rojas IY, Murray IA, Lee S,
Hazlett HF, Perdew GH and Tomlinson CR: Indoleamine 2,3-dioxygenase
1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. Toxicol
Appl Pharmacol. 323:74–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamidullah, Kumar R, Saini KS, Kumar A,
Kumar S, Ramakrishna E, Maurya R, Konwar R and Chattopadhyay N:
Quercetin-6-C-β-D-glucopyranoside, natural analog of quercetin
exhibits anti-prostate cancer activity by inhibiting Akt-mTOR
pathway via aryl hydrocarbon receptor. Biochimie. 119:68–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM,
Tsao JW, Juan YN, Chiu HY, Yang JS and Wang CC: Resveratrol-induced
autophagy and apoptosis in cisplatin-resistant human oral cancer
CAR cells: A key role of AMPK and Akt/mTOR signaling. Int J Oncol.
50:873–882. 2017. View Article : Google Scholar : PubMed/NCBI
|
